November 28, 2022

Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. February 24, 2023

    Fed. Circ. Won't Let Jazz Keep System Patent In Orange Book

    Jazz Pharmaceuticals must remove a patent from the Orange Book listing for its blockbuster narcolepsy drug Xyrem, as it covers neither the drug itself nor a method of using it, the Federal Circuit concluded Friday.

6 other articles on this case. View all »

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login